Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Precision Reasoning In Multimodal Ovarian cancer

Ziel

Ovarian cancer remains the deadliest gynecologic malignancy largely because critical treatment decisions are made under persistent uncertainty. Multidisciplinary tumour boards (MDTs) must choose between competing strategies—primary surgery or neoadjuvant chemotherapy, and alternative maintenance therapies—based on fragmented clinical, imaging and pathology information. Current AI systems, including emerging agentic systems, mainly retrieve guidelines or summarize records; they do not embed a disease-specific computational model of the patient and therefore cannot deliver calibrated prognosis or transparent simulation. PRIMO addresses this gap by developing the first clinical-grade AI decision-support system dedicated to MDT in ovarian cancer. Building directly on the ERC-funded MR-O-MICS project, PRIMO leverages ONCO-IMAGE technologies enabling automated tumour segmentation, quantitative tumour burden estimation and validated morpho-radiomic survival modelling from routine CT and MRI. In collaboration with Synagen, co-founded by ERC laureate Prof. Jakob Kather, PRIMO will integrate imaging, clinical and molecular data into a unified computational patient model capable of generating survival predictions and treatment-aware simulations. The Proof of Concept will deploy and validate PRIMO in real MDT workflows under shadow conditions, demonstrating its ability to provide actionable, quantitative decision support. By transforming fragmented multimodal data into a coherent, predictive and clinically usable model, PRIMO has the potential to fundamentally shift MDT decision-making from qualitative consensus toward quantitative, reproducible and patient-specific treatment selection, with broad applicability across oncology.

Wissenschaftliches Gebiet (EuroSciVoc)

Dieses Projekt wurde noch nicht bei EuroSciVoc klassifiziert.
Schlagen Sie die Wissenschaftsbereiche vor, die Ihrer Einschätzung nach besonders relevant sind, und helfen Sie uns, unseren Klassifizierungsdienst zu verbessern.

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

INSTITUT REGIONAL DU CANCER DE MONTPELLIER
Netto-EU-Beitrag
€ 150 000,00
Adresse
208 AVENUE DES APOTHICAIRES
34298 MONTPELLIER CEDEX 5
Frankreich
Region
Ile-de-France Ile-de-France Paris
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)